Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company's Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International Parkinson...
ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem
A fully connected and integrated approach keeps ZEISS at the forefront of ophthalmology with new data management innovations across devices, workflow solutions and software applications. JENA, Germany and DUBLIN, Calif., Sept. 20, 2021 /PRNewswire/ -- At ZEISS Innovation Week, September 21- 23, 2021, ZEISS Medical Technology will introduce industry-first, integrated solutions that bring further value to the ZEISS Medical Ecosystem, connecting...
PharmAbcine to Participate in BIO-Europe 2021
DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will take place from October 25 - 28, 2021. BIO-Europe is Europe's largest annual partnering conference serving...
CStone presents clinical data from the China registrational bridging study on ivosidenib in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation at the 2021...
The data showed that ivosidenib demonstrated clinical efficacy in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. And ivosidenib was well tolerated and had a manageable safety profile In August 2021, the National Medical Products Administration (NMPA) of China accepted the new drug application (NDA) of ivosidenib for the treatment of adults...
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept. 20, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF)...
P&G partners with Philippine Red Cross for COVID-19 Bakuna Buses in CALABARZON
MANILA, Philippines, Sept. 20, 2021 /PRNewswire/ -- Procter & Gamble (P&G) Philippines continues stepping up as a force for good by supporting the Philippine Red Cross (PRC) mission to assist in the government's national COVID-19 vaccination program. P&G recently donated over 5 million pesos to fund PRC COVID-19 Mobile...
Experts Call on World Leaders to Commit to a Global Plan of Attack on COVID at Summit
More Than 60 Leading Organizations Across Civil Society, Academia, Philanthropy, Health, and Social Enterprise Define a 6-Point Plan to End the Global COVID-19 Crisis SEATTLE, Sept. 20, 2021 /PRNewswire/ -- This week, hosted by the United States, world leaders will gather virtually for the Global COVID-19 Summit: Ending The Pandemic And Building Back Better. According to a group of...
India Ministry of Health and Family Welfare Approves Exablate Neuro Focused Ultrasound Platform
HAIFA, Israel and MIAMI, Fla., Sept. 20, 2021 /PRNewswire/ -- Insightec®, a global healthcare company focused on transforming patient care, announced its incisionless neurosurgery platform, the Exablate® 4000, has received market approval by the Central Drugs Standard Control Organization (CDSCO), part of the Ministry of Health and Family Welfare of India. The Exablate 4000 (Exablate...
Terumo celebrates 100-year anniversary in Asia with an eye to the future
SINGAPORE, Sept. 20, 2021 /PRNewswire/ -- Terumo, a global leader in medical technology, celebrates its centenary in Asia. From humble beginnings as a thermometer manufacturer in 1921, and the first company in 1963 to create disposable syringes in Japan, the company has been providing medical solutions for the healthcare community and quality...
Appealing Data of CARsgen Therapeutics’ CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
SHANGHAI, Sept. 20, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been orally presented at the European Society of Medical Oncology Congress 2021 (ESMO 2021). The presenter was Dr....
